Limitations of Chromogranin A in clinical practice

Biomarkers

Volumn 17, Issue 2, 2012, Pages 186-191

  Marotta, Vincenzo ^a   Nuzzo, Vincenzo ^b   Ferrara, Teresa ^b   Zuccoli, Alfonso ^b   Masone, Milena ^c   Nocerino, Lorenzo ^c   Del Prete, Michela ^a   Marciello, Francesca ^a   Ramundo, Valeria ^a   Lombardi, Gaetano ^a   Vitale, Mario ^d   Colao, Annamaria ^a   Faggiano, Antongiulio ^a,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b San Gennaro Hospital   (Italy)

^c Nuclear Medicine E d'Aosta Hospital   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chromogranin A; Chronic atrophic gastritis; False positive marker; Neuroendocrine tumor; Proton pump inhibitors

Indexed keywords

CHROMOGRANIN A;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NODULAR GOITER;

AGED; CHROMOGRANIN A; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; FEMALE; GOITER, NODULAR; HUMANS; IMMUNORADIOMETRIC ASSAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84857852641     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.654511     Document Type: Article

References (26)

1. Borges R, Díaz-Vera J, Domínguez N, Arnau MR, Machado JD. (2010). Chromogranins as regulators of exocytosis. J Neurochem 114:335-343.
2. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P. (2007). Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967-1973. (Pubitemid 46972778)
3. de Bruïne AP, Wiggers T, Beek C, Volovics A, von Meyenfeldt M, Arends JW, Bosman FT. (1993). Endocrine cells in colorectal adenocarcinomas: incidence, hormone profle and prognostic relevance. Int J Cancer 54:765-771. (Pubitemid 23228607)
4. Edge SB, Byrd DR, Compton CC, et al. (2010). 7th edition AJCC Cancer Staging Manual. New York, NY: Springer.
5. Faggiano A, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, Leboulleux S, Dromain C, Colao A, Schlumberger M, Baudin E. (2007). Pulmonary and extrapulmonary poorly diferentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 110:265-274. (Pubitemid 47121885)
6. Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, Del Basso De Caro ML, Milone F, Scarpelli G, Masone S, Santeusanio F, Lombardi G, Angeletti G, Colao A. (2008). Te biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest 31: 277-286. (Pubitemid 351638409)
7. Glinicki P, Jeske W. (2010). Chromogranin A (CgA)-the infuence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood. Endokrynol Pol 61:384-387.
8. Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. (1999). Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85:1470-1483. (Pubitemid 29152818)
9. Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, Skogseid B. (1999). Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 84:2712-2717. (Pubitemid 30641998)
10. Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M, Baudin E. (2001). Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer 84:808-812. (Pubitemid 32275655)
11. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. (2010). Te pathologic classifcation of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707-712.
12. Klöppel G, Solcia E, Capella C, Heitz PU. (1999). Classifcation of neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2:S111-S116.
13. Kuipers EJ. (2006). Proton pump inhibitors and gastric neoplasia. Gut 55:1217-1221. (Pubitemid 44277346)
14. Milione M, Seregni E. (2010). Pathological diagnosis and tumor markers. Tumori 96:810-816.
15. Nobels FR, Kwekkeboom DJ, Coopmans W, Hoekstra R, De Herder WW, Bouillon R, Lamberts SW. (1993). A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit- secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 77:784-789. (Pubitemid 23298667)
16. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW. (1997). Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specifc enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82:2622-2628. (Pubitemid 27337883)
17. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. (1989). Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the efects of organ failure. Clin Chem 35:1631-1637. (Pubitemid 19212423)
18. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape U F, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 90:194-202.
19. Scopsi L, Andreola S, Pilotti S, Testori A, Baldini MT, Leoni F, Lombardi L, Hutton JC, Shimizu F, Rosa P. (1992). Argyrophilia and granin (chromogranin/secretogranin) expression in female breast carcinomas. Teir relationship to survival and other disease parameters. Am J Surg Pathol 16:561-576.
20. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. (2001). Clinical signifcance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12 Suppl 2:S69-S72. (Pubitemid 33069690)
21. Solcia E, Kloppel G, Sobin LH et al. (2000). Histological Typing of Endocrine Tumours (World Health Organization. International Classifcation of Tumours) 2nd edn. Heidelberg: Springer-Verlag.
22. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. (1991). Neuroendocrine diferentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer 64:333-338.
23. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'Connor DT. (1990). Chromogranin A. Storage and release in hypertension. Hypertension 15:237-246. (Pubitemid 20097450)
24. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA. (1995). Chromogranin A in human hypertension. Infuence of heredity. Hypertension 26:213-220.
25. Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d'Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M, Baudin E. (2011). Chromogranin A measurement in metastatic well-diferentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 26:94-101.
26. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC; Italian CromaNet Working Group. (2007). Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 14:473-482. (Pubitemid 47242645)